Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Despite carbohydrates being an essential macronutrient, when it comes to weight loss, carbs like pasta, rice, corn, bread and ...

Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...

A father is a girl's first male relationship. But what happens when that bond is shaken? Two ABC colleagues looked to explore that in this three-part series as they grapple with the loss of their own ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Top medics have issued urgent warnings after fat jabs including celebrity favourite Ozempic are inked with 82 deaths, as drug ...